Vanguard Group has struck a roughly USD 4bln deal to acquire fintech platform Altruist to further its push into financial advice, reports WSJ citing sources
Newsquawk Staff ·
- Altruist is an upstart competitor to Charles Schwab (SCHW) and Fidelity Investments in providing custodial and administrative work to independent financial advisers.
What it means
A source-based report rather than a confirmed announcement, so the first tell is whether the parties confirm terms and timing; deals of this size reported from sources have historically either been formalised within days or walked back on valuation and structure. Strategically this fits a well-established pattern among large asset managers of buying distribution and advice infrastructure rather than building it, as the economics of the industry have shifted from product manufacturing toward owning the adviser relationship and the custodial layer beneath it. Altruist sits in the independent adviser custody niche where Schwab and Fidelity dominate, so the competitive read runs through that peer set: an incumbent with a subscale but modern custodial platform changes hands to a buyer with the balance sheet to fund a price and technology war. Prior form matters here: Vanguard has historically expanded organically and priced aggressively rather than paying for acquisitions, so an out-of-character purchase of this kind would signal how seriously it rates the advice channel. The follow-ons are confirmation, regulatory posture on custody concentration, and any read-across in the listed custodians, where precedent on strategic consolidation in adviser services has tended to compress the target niche's economics rather than the incumbents' share price durably.
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation
- American Express (AXP) to cut 5% of jobs
Related headlines
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM1 hour ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years2 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months3 hours ago
- American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)3 hours ago
- Booz Allen (BAH) Q2 2026 (USD): Adj. EPS 1.76 (exp. 1.48), Revenue 2.80bln (prev. 2.81bln)3 hours ago
- SLB (SLB) Q3 2026 (USD): adj. EPS 0.64 (exp. 0.62), Revenue 9.45bln (exp. 9.27bln)3 hours ago
- Citi (C) has been granted approval by China for its securities unit6 hours ago
- Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand14 hours ago
- OpenAI trims valuation target to USD 1.25tln after previously pitching a higher price, according to FT16 hours ago
- Newmont (NEM) says production growth is expected to begin in 2027 following previously flagged 2026 trough, adds Q3 gold production was broadly flat sequentially as anticipated16 hours ago
- SpaceX (SPCX) in talks to access 80,000 cell sites for new network16 hours ago
- Google (GOOG) announces general availability of an Anthropic-managed deployment option for Claude models on Google Cloud17 hours ago
- OpenAI is raising up to USD 30bln in funding round at a USD 1.25tln valuation, led by UAE investors, according to CNBC, citing sources; OpenAI is negotiating a commercial deal that would secure more computing capacity from the UAE18 hours ago
- Gilead Sciences (GILD) entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited; deal valued at USD 1.27bln in upfront cash18 hours ago
- Newmont (NEM) Q3 2026 (USD): Adj. EPS 2.20 (exp. 2.06), Revenue 6.36bln (exp. 6.30bln), Adj. EBITDA 3.95bln (exp. 3.73bln)18 hours ago